Scarica l'app Stockscreener
4.82
13.95%
0.59
Precedente Chiudi:
$4.23
Aprire:
$4.19
Volume 24 ore:
51,095
Relative Volume:
0.80
Capitalizzazione di mercato:
$3.07M
Reddito:
$5.49M
Utile/perdita netta:
$-6.35M
Rapporto P/E:
-0.9112
EPS:
-5.29
Flusso di cassa netto:
$-6.51M
1 W Prestazione:
-5.12%
1M Prestazione:
-16.90%
6M Prestazione:
-26.79%
1 anno Prestazione:
-36.60%
Intervallo 1D:
$4.09
$4.99
Intervallo di 1 settimana:
$3.65
$5.1341
Portata 52W:
$2.414
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Nome
Inmed Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 669-7207
Indirizzo
1445-885 WEST GEORGIA ST., VANCOUVER
Confronta INM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| INM | 4.8319 | 3.07M | 5.49M | -6.35M | -6.51M | -5.29 |
| VRTX | 449.26 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.01 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 600.42 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.36 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.11 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Book pe - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PS Rati - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Book Growth Rate : -64.40% (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Current Liabilities : €0.21 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS (Basic) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long-Term Liabilities : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Discontinued Inve - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long Term Assets : €0.09 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Ratio : 3.89 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Investing : €-0.01 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EBIT : €-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Peter Lynch Fair Value : €-1,493.15 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Other Investing A - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Long-Term Capital Lease Obl - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Total Stockholders Equity : €7.56 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EV-to-EBITDA : 0.22 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Revenue per Share : €68.91 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Receivables : €-0.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year EPS without NRI Grow - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS without NRI : €-59.73 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Stockholders Equity : €-0.00 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Inventory : €-0.28 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Issuance of Preferred S - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Short-Term Capital Lease Ob - GuruFocus.com
InMed’s Study Highlights Cannabinol’s Potential in Skincare - TipRanks
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System - Newsfile
InMed Pharmaceuticals Reports Improved Quarterly Earnings - TipRanks
InMed Pharmaceuticals (STU:MWG) Debt-to-EBITDA : -0.13 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Growth Rank : 0 (As of Nov. 17, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Issuance of Stock : €4.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Working Capital : €-0.33 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Repurchase of Stock : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Inventory-to-Revenue : 0.95 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Financing : €4.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Deferred Tax : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year EBITDA Growth Rate : 70.10% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Retained Earnings : €-101.33 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) ROE % Adjusted to Book Value : -14.96% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 50-Day SMA : €4.49 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) FCF Yield % : -226.50 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) PE Ratio without NRI : At Loss (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Volatility : 115.20% (As of Nov. 16, 2024) - GuruFocus.com
Inmed Pharmaceuticals Inc Azioni (INM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inmed Pharmaceuticals Inc Azioni (INM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HULL ANDREW | Director |
Feb 21 '24 |
Buy |
0.39 |
37,500 |
14,625 |
38,258 |
| ADAMS ERIC A | President & CEO |
Feb 20 '24 |
Buy |
0.36 |
41,600 |
14,922 |
43,959 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):